References
- Buchwald H. The evolution of metabolic/bariatric surgery. Obes Surg. 2014;24:1126–1135.
- Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Reviews: Official Journal Int Assoc Study Obes. 2010;11:41–50.
- Tandra S, Chalasani N, Jones DR, et al. Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg. 2013;258:262–269.
- Lloret-Linares C, Hirt D, Bardin C, et al. Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach. Clin Pharmacokinet. 2014;53:919–930.
- Lloret-Linares C, Miyauchi E, Luo H, et al. Oral morphine pharmacokinetic in obesity: the role of P-glycoprotein, MRP2, MRP3, UGT2B7, and CYP3A4 jejunal contents and obesity-associated biomarkers. Mol Pharm. 2016;13:766–773.
- Mitrov-Winkelmolen L, Van Buul-Gast MC, Swank DJ, et al. The effect of Roux-en-Y gastric bypass surgery in morbidly obese patients on pharmacokinetics of (acetyl)salicylic acid and omeprazole: the ERY-PAO study. Obes Surg. 2016;26:2051–2058.
- Hamad GG, Helsel JC, Perel JM, et al. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry. 2012;169:256–263.
- Roerig JL, Steffen K, Zimmerman C, et al. Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. Surg Obes Relat Dis. 2012;8:62–66.
- Roerig JL, Steffen KJ, Zimmerman C, et al. A comparison of duloxetine plasma levels in postbariatric surgery patients versus matched nonsurgical control subjects. J Clin Psychopharmacol. 2013;33:479–484.
- Gesquiere I, Darwich AS, Van Der Schueren B, et al. Drug disposition and modelling before and after gastric bypass: immediate and controlled-release metoprolol formulations. Br J Clin Pharmacol. 2015;80:1021–1030.
- Ulvestad M, Skottheim IB, Jakobsen GS, et al. Impact of OATP1B1, MDR1, AND CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. Clin Pharmacol Ther. 2013;93:275–282.
- Miyauchi E, Tachikawa M, Decleves X, et al. Quantitative atlas of cytochrome P450, UDP-glucuronosyltransferase, and transporter proteins in jejunum of morbidly obese subjects. Mol Pharm. 2016;13:2631–2640.
- Hertz DL, Deal A, Ibrahim JG, et al. Tamoxifen dose escalation in patients with diminished CYP2D6 activity normalizes endoxifen concentrations without increasing toxicity. Oncologist. 2016;21:795–803.
- Padwal RS, Gabr RQ, Sharma AM, et al. Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care. 2011;34:1295–1300.